Author

Mark E. Jonas

Observed names: M. Jonas, Mark E Jonas, Mark Jonas

Institution: Ohio Gastroenterology and Liver Institute

Observed institutions: Bethesda North Hospital, Ohio Gastroenterology and Liver Institute, University of Cincinnati, Jewish Hospital

ORCID: 0000-0002-1526-2164

Observed ORCID: 0000-0002-1526-2164

OpenAlex ID: A5102990566

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

2017 · David Jones, Pol F Boudes, et al. · The Lancet. Gastroenterology & hepatology · 195

Farglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection

2009 · John McHutchison, Zachary Goodman, et al. · Gastroenterology · 91

Analysis of Hospitalizations Comparing Rifaximin Versus Lactulose in the Management of Hepatic Encephalopathy

2006 · G.W. Neff, N. Kemmer, et al. · Transplantation Proceedings · 60

Lack of Clostridium difficile Infection in Patients Treated With Rifaximin for Hepatic Encephalopathy

2013 · Guy W. Neff, Michael Jones, et al. · Journal of Clinical Gastroenterology · 31

Adult Onset Urea Cycle Disorder in a Patient With Presumed Hepatic Encephalopathy

2008 · Muslim Atiq, Andrew F. Holt, et al. · Journal of Clinical Gastroenterology · 28

Durability of Rifaximin Response in Hepatic Encephalopathy

2011 · Guy W. Neff, Michael Jones, et al. · Journal of Clinical Gastroenterology · 27

An international double-blind placebo-controlled trial of lamivudine in 286 children with chronic hepatitis B (CHB)

2001 · E.M. Sokal, D. Kelly, et al. · Journal of Hepatology · 5

Hemochromatosis in a Female With Homozygous H63d Gene Mutation and Hepatitis C With Autoimmune Features

2003 · Geoffrey A. Rose, Mark E. Jonas · The American Journal of Gastroenterology

Works count: 8

Citation count: 437

H-index: 6

I10-index: 6